Background-In a whole-genome scan, a single nucleotide polymorphism (SNP) (rs7566605) upstream of the insulin-induced gene 2 (INSIG2) was shown to influence body mass index and obesity in the Framingham Heart Study, with replication of these results in an additional 4 of 5 studies. However, other studies could not replicate the association.
A n association between a single nucleotide polymorphism (SNP) (rs7566605) in the insulin-induced gene 2 (IN-SIG2) and body mass index (BMI) was discovered in a genome-wide scan of 86 604 SNPs in 923 individuals from the Framingham Heart Study. 1 The association was replicated in an additional 4 of 5 independent study samples composed of western Europeans and blacks. 1 A follow-up study reproduced this result in 5 of 9 samples. 2 However, subsequent studies performed by other groups could not replicate the association. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] A recent meta-analysis suggested that different study designs might have contributed to these heterogeneous results. 15 
Clinical Perspective on p 461
Although the physiologic role of INSIG2 in obesity is unclear, there is strong evidence suggesting that the gene plays a key role in both fatty acid and cholesterol biosynthesis. Double-knockout mice containing germline disruption of INSIG2 and liver-specific disruption of the INSIG1 had 4-fold increases in plasma cholesterol levels and a 6-fold increase in plasma triglyceride levels compared with controls. The knockout mice also had enlarged livers because of lipid accumulation. 16 In addition, overexpression of INSIG2 in Zucker diabetic fatty rats significantly decreased hepatic triglycerides and liver steatosis. 17 INSIG2, along with INSIG1, plays a major role in regulating intracellular cholesterol levels by preventing sterol regulatory element-binding protein-2, a transcription factor for cholesterol biosynthesis enzymes, from entering the nucleus under conditions of high intracellular cholesterol. INSIG proteins release sterol regulatory element-binding protein-2 from the endoplasmic reticulum for nuclear processing when cells are deprived of exogenous cholesterol. 18 Expression of the gene is also increased in fasted mice and repressed when the mice are refed, 19 suggesting that the gene is insulin-responsive. Most significantly, INSIG2 has been identified as a strong candidate gene for plasma cholesterol levels in mice fed a high-fat diet. 20 A limitation of previous gene association studies involving INSIG2 is that they have all focused on a single SNP (ie, rs7566605) and/or on 1 trait (obesity or BMI). The inconsistency of the association with obesity among studies could be due to differential linkage disequilibrium (LD) with a causal SNP or differential correlation of BMI with a more proximal phenotype. Interactions with the environment and other genes may also contribute to the heterogeneity among these studies.
In the present study, we undertook a detailed, comprehensive analysis of INSIG2 variants to investigate the hypothesis that INSIG2 variants play a major role in human plasma lipid and lipoprotein levels. In addition, we investigate the combined effect of INSIG2 variants with an SNP in the human sorbin and SH 3 -domain-containing-1 gene (SORBS1), a gene involved in insulin receptor-mediated signaling.
Methods

Study Populations
The initial screening stage was performed in 645 individuals from 186 French-Canadian families in the Quebec Family Study (QFS). Some probands in the QFS were selected for obesity. 21 Our second study sample was composed of 224 individuals from a case-control sample of coronary heart disease and 534 individuals from 127 families with at least 1 coronary heart disease proband, for a total of 758 individuals, from the Saguenay-Lac St. Jean (SLSJ) region of Quebec. 22 Families of individuals who were homozygous for a low-density lipoprotein (LDL) receptor mutation were excluded. Our third study sample comprised 3713 Europeans and 1695 South Asians from the INTERHEART (IH) study, 23, 24 a global case-control study of myocardial infarction.
Details of the acquisition of clinical phenotypes for the QFS, SLSJ study, and IH study can be obtained from Bossé et al, 25 Paré et al, 22 and Yusuf et al, 26 respectively. Lipid values were taken from blood samples in individuals after an overnight fast in both the QFS and SLSJ study and from blood samples in nonfasting individuals in the IH study. 26 Individuals who were taking cholesterol-lowering medications were excluded from the analysis.
Tagging SNP Selection
We selected tagging SNPs (tSNPs) from the HapMap phase 2 CEU data set by using Haploview. 27 SNPs with minor allele frequencies Ͼ0.05 and a pairwise r 2 Ͼ0.80 were used for selection of tSNPs.
Sequencing
Predicted cis-regulatory modules (CRMs) in the INSIG2 locus region were identified by using the PReMod program. 28 All CRMs upstream of INSIG2 were sequenced in 12 individuals with high levels of LDL cholesterol (LDL-C; meanϮSD, 6.13Ϯ0.83 mmol/L, Ͼ99th percentile of LDL-C distribution) and 12 individuals with low levels of LDL-C (meanϮSD, 1.21Ϯ0.45 mmol/L, below the first percentile of LDL-C distribution). Polymerase chain reaction conditions included 2.5 L polymerase chain reaction buffer (Qiagen, Mississauga, Canada), 0.5 L of 40 mol/L deoxynucleotides (Invitrogen Canada Inc, Burlington, Canada),), 1 L of 20 mol/L primers (Integrated DNA Technologies, Coralville, Iowa), and 0.1 L of HotStarTaq (Qiagen) in a 25-L reaction. The polymerase chain reaction for some target sequences was further optimized and amplified with 5 L of Q solution (Qiagen) and/or 2.5 L MgCl 2 (Qiagen). Purification of the polymerase chain reaction products was performed with Multiscreen (Millipore, Bedford, Mass), and they were sequenced with BigDye Terminator (version 3.1) on ABI 3730 XL DNA analyzers (Applied Biosystems, Foster City, Calif). Data were analyzed by Sequencing Analysis software (version 5.1) and aligned by Phred, Phrap, and Consed. 29
Genotyping and Imputation
The SNP rs10490626 was genotyped in the SLSJ study by using a functionally tested Taqman assay (C_30054997_30, Applied Biosystems) according to the manufacturer's instructions and as previously described. 30 Genotyping for the QFS samples, IH South Asian samples, and 1718 individuals in the IH European sample was performed by using the Sequenom iPLEX Gold Assay (Sequenom, Cambridge, Mass) as previously described, 31 and all SNPs had call rates Ն97%. Missing genotypes were inferred in an additional 1634 individuals from the IH European sample by using a hidden Markov model implemented in the MACH program. 32 This method can predict the expected number of copies of the minor allele of any given SNP ("allele dosage") based on the shared haplotypes between the study sample and a reference sample, in this case, HapMap CEU. 32 A strict quality-control measure was used to exclude imputed scores of insufficient quality (posterior probability Ͻ0.95). This resulted in the exclusion of Ͻ10% of the samples. Genotype counts for rs10490626 in QFS are 790, 107, and 3; for SLSJ, 1194, 176, and 5; and for IH South Asians, 2245, 298, and 8 for CC, CT, and TT genotypes, respectively. Allele dosages for IH Europeans were used, and therefore, counts are not provided. Fourteen SNPs in the INSIG2 locus region were used for the imputation and have been previously described. 22
Statistical Analyses and Association Testing
Deviations from Hardy-Weinberg equilibrium were determined with the exact test in Pedstats 33 or Pearson's goodness-of-fit 2 test (available athttp://ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl). Association testing for plasma LDL-C, total apolipoprotein B (apoB) levels, and BMI in the QFS and the SLSJ study was performed with a mixed-effects regression model 31 with SAS (version 8.2; SAS Institute, Cary, NC). Familial structure in the QFS and SLSJ study was accounted for by using a sandwich estimator, which estimates the correlations within a family by correcting for the standard errors of the dependencies. Association testing in the IH study was performed by using linear regression. Population stratification in the IH study sample was corrected for by adjusting for study center. 23 Total apoB values were transformed by using the natural log in the SLSJ study to produce a more normal distribution. Age, sex, smoking status, affected status (coronary heart disease for the SLSJ and myocardial infarction for the IH study), and BMI were adjusted for in all regression models, except when testing for BMI, for which only age, sex, smoking status, and affected status were included. Significance was set at PϽ0.05, with 2-sided probability values being reported for stage 1 (discovery) and 1-sided probability values for stage 2 (replication). Meta-analysis was performed with a weighted Z-method with weights proportional to the square root of the number of individuals analyzed in each study 34 and statistical significance defined as PϽ0.0016.
Identification of SORBS1 as a Regulator of INSIG2 mRNA
Trans associations for gene expression have a much higher likelihood of being false-positives compared with cis associations owing to the larger number of statistical tests and lower a priori likelihood of true expression association. Furthermore, different expression platforms often yield discordant expression data (reviewed by Cookson et al 35 ). To overcome these concerns, we used a 2-stage approach. First, using the largest completely publicly available expression quantitative trait loci dataset in human lymphoblasts (LCLs) from white donors, 36 we identified the top 100 SNP associations for INSIG2 expression levels. The subset of genic SNPs was examined in 2 study samples by 2 different expression techniques: All-Exon arrays from Affymetrix 37 and Illumina Human vs.6 arrays 38 to replicate the trans associations by independent expression array methods. Only 1 SNP (rs1326934) in SORBS1 demonstrated an association in all 3 samples.
Results
We selected tSNPs for the INSIG2 region from the 5Ј end of a 70-kb intergenic/promoter region to the 3Ј end of INSIG2 for a total of Ͼ100 kb (Figure 1 ). We identified 35 tSNPs, including the SNP that was originally associated with obesity (rs7566605). 1 To supplement our tSNPs, sequencing was performed to identify novel, common SNPs in putatively functional regions of the locus. We sequenced the exons, intron-exon boundaries, and predicted CRMs in 12 individuals with high LDL-C levels (mean, 6.13 mmol/L) and 12 individuals with low LDL-C levels (1.21 mmol/L; Figure 1 ). A total of 18 434 bp were sequenced. No nonsynonymous SNPs were discovered. We identified 37 SNPs (Table in the onlineonly Data Supplement), of which 21 were not in the HapMap. Seventeen of these 21 were either rare (minor allele frequencies Ͻ0.04) or in perfect LD with 1 of the tSNPs. We added the remaining 4 SNPs to our set of tSNPs. This included 2 polymorphisms upstream of the gene (Ϫ41039C3 G and Ϫ35037delA), a 3Ј untranslated region SNP (c.1777C3 T), and the SNP Ϫ102GϾA, which had also been previously associated with BMI. 39 Thus, 39 SNPs in the INSIG2 locus were selected for genotyping ( Figure 1 ).
Association Testing With LDL-C, Total ApoB, and BMI in the QFS
These SNPs were genotyped in 645 individuals from the QFS ( Table 1) . Three SNPs failed genotyping and 4 were monomorphic, leaving 32 SNPs available for association analysis. All SNPs were in Hardy-Weinberg equilibrium, except for rs1547998 (Pϭ0.033). We found no association between any of the 32 SNPs in INSIG2 and BMI in the QFS under an additive model (all PϾ0.05; Table 2 ). In addition, in contrast 
Replication of Association Results in the SLSJ and IH Studies
Because rs10490626 and rs12464355 were in LD, we attempted to replicate only 1 of the SNPs (rs10490626) in a coronary heart disease study sample of 758 individuals from the founder population of SLSJ (Table 1 ). rs10490626 was selected because it was predicted to have a functional effect, as it was in perfect LD with another SNP, rs17526895, that lies in a CRM (module1_hg17_mod060530, 28, 40 ) , which is 30 kb upstream of INSIG2 (based on Entrez gene ID 51141). Consistent with the results from the QFS, rs10490626 was associated with both LDL-C (1-sided Pϭ0.040) and total apoB (1-sided Pϭ0.044) but not with BMI (2-sided Pϭ0.98; Table 2 ). We genotyped rs10490626 in 1718 individuals and imputed missing genotypes for an additional 1634 individuals (see Methods) for a total of 3352 Europeans from the IH study of myocardial infarction (Table 1) . We replicated the effect of the SNP on both LDL-C (1-sided Pϭ0.028) and total apoB (1-sided Pϭ0.030; Table 2 ). We also genotyped this SNP in 1695 South Asians from the IH study and found consistent associations of this SNP with both LDL-C (1-sided Pϭ0.0036) and total apoB (1-sided Pϭ0.034). A meta-analysis of all study samples combined displayed a strong association with both traits (for LDL-C, 2-sided Pϭ6.2ϫ10 Ϫ5 and for total apoB, 2-sided Pϭ0.0011). In the IH study, no effect was seen with this SNP on BMI in either Europeans or South Asians (all PϾ0.05; Table 2 ). Evidence for deviations from an additive model were not apparent, as weaker associations were found for rs10490626 with both LDL-C and total apoB under either a recessive or a dominant model in the QFS, SLSJ study, and IH study (data not shown). No significant differences of the effect of rs10490626 were observed between males and females (data not shown).
Effect of BMI on the Association of rs10490626 and LDL-C Levels
We investigated the effect of obesity on the association of rs10490626 and LDL-C levels. In our study, the association of rs10490626 with LDL-C levels was strongest in moreobese individuals (BMI greater than the median of 26.46 kg/m 2 , Pϭ0.0016) when compared with less-obese individuals in both the QFS (BMI less than the median, Pϭ0.013) and SLSJ study (BMI more than the median of 26.85 kg/m 2 , 1-sided Pϭ0.041, vs BMI less than the median, Pϭ0. 21) . No effect of obesity was seen in the IH study.
Effect of INSIG2 and SORBS1 in the QFS and IH Study
We performed an in silico genome-wide scan of publicly available data for trans-acting SNPs of INSIG2 mRNA abundance (PϽ0.05). We identified an SNP in SORBS1 (rs1326934) on chromosome 10 (log of the odds scoreϭ2.875) 36 displaying a trans effect on INSIG2 mRNA (see Materials and Methods). This result was replicated in 2 studies carried out on HapMap CEU LCL human lymphoblasts 37, 38 (Pϭ0.0075 and Pϭ0.05, 1-sided linear-regression test). This was the only trans effect on INSIG2 expression mapping to a known gene and demonstrating a consistent effect in 3 studies among the top 100 significant associations observed in the expression quantitative trait loci study by Dixon et al. 36 rs1326934 was not independently associated with either LDL-C or total apoB in the QFS (PϾ0.05). However, this SNP, in combination with rs10490626, significantly influenced plasma LDL-C levels (effectϭ0.096 mmol/L, Pϭ0.022) (Figure 2 ), and demonstrated a trend with total apoB (ef-fectϭ0.021 mmol/L, Pϭ0.052) in the QFS. We replicated this 2-locus additive effect of rs10490626 in INSIG2 and of rs1326934 in SORBS1 for LDL-C in 1695 South Asians from the IH study (effectϭ0.037, 1-sided Pϭ0.019) but not with total apoB (effectϭ0.0089, 1-sided Pϭ0.12). A trend of the 2-locus additive effect of rs10490626 and rs1326934 was also observed in 1718 Europeans for LDL-C (effectϭ0.052, 1-sided Pϭ0.057) and apoB (effectϭ0.013, 1-sided Pϭ0.053).
Discussion
We report an SNP that was consistently associated with both plasma LDL-C and total apoB levels in 3 independent studies. This result was seen not only in Europeans but also in South Asians, suggesting that the finding may extend to multiple ethnicities. The consistent effect observed with both plasma lipid and lipoprotein traits suggests that INSIG2 may play a much more important role in lipid metabolism than in obesity. Our results are consistent with those of Cervino et al, 20 who observed a quantitative trait locus in mice for the expression of INSIG2 mRNA, as well as quantitative trait loci for both LDL and VDL and total cholesterol levels that mapped to the INSIG2 locus.
The genetic variant of INSIG2 that was recently implicated in obesity through a genome-wide association study performed in the Framingham Heart Study 1 has been inconsistently replicated by other research groups. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] In the present study, using 32 SNPs, we show that a dense map of the INSIG2 locus, including the previously reported SNP, rs7566605, did not yield a significant association with BMI. The lack of reproducibility of rs7566605 with obesity seen in our study could be due to several reasons, including insufficient power, heterogeneity of ascertainment, and/or unknown gene-gene or gene-environment interactions. Age has also been suggested to contribute to the estimated risk of the allele, where the result is strongest in the first 3 measurements when compared with the last 3 measurements of the longitudinal Framingham Heart Study offspring study. 2 In addition, the result has been reported to be strongest in obese individuals. 1, 2, 15 Herbert et al 1 reported that replication of rs7566605 and obesity was achieved in all study samples except in the Nurses' Health Study, which interestingly had a much lower mean BMI than the other study samples. Lyon et al 2 also noted a stronger effect of the SNP in the most severely obese individuals (BMI Ͼ38 kg/m 2 ) in the KORA S3 study (odds ratioϭ1.78, Pϭ0.054). This may be due to individuals becoming more obese at an earlier age. 2 However, in the QFS, we did not find an interaction of either age or obesity with the effect of rs7566605 on BMI (data not shown).
It is possible that obesity may act as a modifier on the action of INSIG2 variants on lipid-related traits because the strongest association of rs10490626 and LDL-C levels was found in the QFS, which had the highest mean BMI of the 4 samples analyzed (QFS, SLSJ, IH Europeans, and South Asians), and stronger associations were found in the moreobese individuals when compared with the less-obese individuals in the QFS and SLSJ study. Baseline mRNA levels of INSIG2 do not differ between Zucker diabetic fatty rats and lean, wild-type Zucker diabetic fatty rats 17 ; however, overexpression of INSIG2 decreases hyperlipidemia and liver steatosis in Zucker diabetic fatty rats. 17 The SNP rs10490626 is Ϸ12 kb upstream of INSIG2 and is in perfect LD with another SNP, rs17526895, that lies in a CRM (module1_hg17_mod060530, 28, 40 ) and a constrained genomic interval (mean phyloP is 2.55 for the 8-bp region, which represents the Ϫlog probability value under a null hypothesis of neutral evolution, based on multiple alignments of 44 vertebrate species from the Vertebrate Multiz Alignment and Conservation track of the UCSC Santa Cruz Genome Browser), indicating a strong level of conservation. This region was predicted to have a binding site for hepatic nuclear factor-3␤ based on the PROMO server, 41 a transcription factor that regulates lipid metabolism in the liver, 42 suggesting a possible mechanism for the effect of the genetic variation. A 2-locus additive effect was also seen between rs10490626 of INSIG2 and rs1326934 of SORBS1 on LDL-C and total apoB in the QFS. The results were confirmed for LDL-C in 1695 South Asians and 1718 Europeans from the IH study. These results are interesting because both INSIG2 and SORBS1 are also involved in insulin signaling. SORBS1 is an adaptor protein involved in insulin-stimulated glucose uptake, 43 whereas INSIG2 expression is repressed in insulintreated rat hepatocytes but is activated in insulin-deficient rats. 19 Whole-body and tissue-specific deletion of SORBS1 also confers protection against high-fat diet-induced insulin resistance, 44 and SNPs in the gene have also been previously reported to be associated with both obesity and diabetes. 45 Both SORBS1 and INSIG2 are expressed in lymphoblasts, and although our discovery was in lymphoblasts, the expression quantitative trait loci results for SORBS1 and INSIG2 could be consistent in other cell types, as expression variation in lymphocytes has been shown to have a strong correlation with expression variation in other tissue or cell types. 46, 47 We note that 1 study has shown a significant association of rs10490626 with BMI, 48 a finding that we did not confirm, but this related result was observed in Hispanic Americans and the authors did not test for an association with lipid traits. Thus far, only 1 association study involving INSIG2 has examined lipid traits, 13 and it reported no association of rs7566605 (the only SNP examined) with plasma total cholesterol, LDL-C, high-density lipoprotein cholesterol, triglycerides, and free fatty acid levels. This highlights 1 of the strengths of the present study, which used both sequencing and tagging methods to select multiple SNPs for association testing that capture much of the genetic variation at the locus. In conclusion, the SNP rs10490626, 10 kb upstream of INSIG2, is consistently associated with both LDL-C and total apoB levels in a total of 6450 individuals from 3 independent study samples, including 2 different ethnicities. Further research is needed to determine the functional role of this SNP and its possible differential response to diet.
While our manuscript was under review, the global lipids genetics consortium published their genome-wide association findings from a meta-analysis of Ͼ95,000 individuals. 49 In their publicly available data set (http://www.broadinstitute. org/mpg/pubs/lipids2010/ or http://www.sph.umich.edu/csg/ abecasis/public/lipids2010/), the SNP rs10490626 was significantly associated with LDL-C (pϭ1.06ϫ10Ϫ7) and was the most significant finding within 100 KB of the INSIG2 gene. We believe this independent replication strongly supports the results presented in this paper. 
